Responsibility for patient education in drug therapy from the viewpoint of the drug industry
Lerch, C.
Zeitschrift für Arztliche Fortbildung 88(12): 1055-1060
1994
ISSN/ISBN: 0044-2178 PMID: 7716982 Document Number: 438875
Document emailed within 1 workday
Related Documents
Ludwig, W.D. 1997: Patient education responsibility, specialty and administration information from the internal medicine viewpoint Zeitschrift für Arztliche Fortbildung und Qualitatssicherung 91(7): 657-661Eliasson, G.; Håkansson, J. 2001: Keep medical education independent! it should not be a scene of drug industry marketing Lakartidningen 98(39): 4168-4169
Midford, R.; Cahill, H.; Foxcroft, D.; Lester, L.; Venning, L.; Ramsden, R.; Pose, M. 2012: Drug education in Victorian schools (DEVS): the study protocol for a harm reduction focused school drug education trial Bmc Public Health 12: 112
Robinson, D.S. 1994: Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. a pharmaceutical industry perspective on drug labeling Psychopharmacology Bulletin 30(1): 23-25
Armetti, L. 1999: Round table: The Italian Pharmacology Society and the drug industry: new processes in drug discovery and the contribution of universities Bollettino chimico farmaceutico 138(11): 596-598
Modestin, J. 1970: Psychotropic drug therapy and pharmaceutical industry Arzneimittel-Forschung 20(7): 877-879
Wehling, M.; Peiter, A. 2003: Drug therapy of elderly patients from the viewpoint of the clinical pharmacologist Der Internist 44(8): 1003-1009
Sugama, M.; Ishizaki, A. 2014: Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate No to Hattatsu 46(1): 22-25
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Gupta, R.; Wu, J.J.; Levin, E.; Koo, J.Y.M.; Liao, W. 2013: Possible drug-drug interaction between adalimumab and duloxetine and/or pregabalin in a psoriasis patient Journal of Drugs in Dermatology: Jdd 12(10): 1089
Pleasants, R.A.; Kessler, J.M. 1993: Drug allergies, adverse drug reactions, and the patient record American Journal of Hospital Pharmacy 50(7): 1363
Schwabe, U. 1980: The influence of the drug legislation on drug information for the physician and patient Der Internist 21(6): 311-317
Oehme, P.; Brüschke, G.; Kluchert, K.; Krüger, U. 1970: Current problems of drug therapy. 9. Stationary and ambulatory drug therapy. 2 Das Deutsche Gesundheitswesen 25(21): 957-960
Fallor, M.K. 1981: Drug therapy and the geriatric patient Delaware Medical Journal 53(5): 263-267
Joshi, P.P. 1999: Patient compliance with drug therapy Journal of the Association of Physicians of India 47(6): 655-656
Scotson, J.H. 1984: Patient opinion and drug therapy Practitioner 228(1393): 669-672
Assal, J.P.; Lacroix, A.; Dayer, P. 1986: Analysis of the effect of a drug. a model for studying the education of patient in the treatment of his disease over a long period Journees Annuelles de Diabetologie de l'Hotel-Dieu 1986: 285-294
Fujii, Y. 2001: Acute phase drug therapy and drug switching in the treatment of patients with schizophrenia Seishin Shinkeigaku Zasshi 103(12): 1030-1035
Vozeh, S. 1984: Drug level determination for optimization of drug therapy. Practical significance and new trends Schweizerische Rundschau für Medizin Praxis 73(49): 1505-1506
Bunton, R.W. 1983: Reintroduction of anti-inflammatory drug therapy after drug-associated gastrointestinal disturbances New Zealand Medical Journal 96(726): 144